We could not find any results for:
Make sure your spelling is correct or try broadening your search.
TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing - TapImmune Inc. changes name to Marker Therapeutics, Inc. - To Commence Trading on...
TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant Mayo Clinic Receives...
TapImmune to Present at Two Upcoming Investor Conferences PR Newswire JACKSONVILLE, Fla., Sept. 25, 2018 JACKSONVILLE, Fla., Sept. 25, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a...
TapImmune To Present at 2018 Janney Healthcare Conference PR Newswire JACKSONVILLE, Fla., Sept. 12, 2018 JACKSONVILLE, Fla., Sept. 12, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a...
TapImmune to Participate at Two Upcoming Industry Conferences PR Newswire JACKSONVILLE, Fla., Aug. 29, 2018 JACKSONVILLE, Fla., Aug. 29, 2018 /PRNewswire/ --TapImmune Inc. (NASDAQ: TPIV), a...
TapImmune Announces Pricing of $70 Million Private Placement Financing Led by New Enterprise Associates (NEA) Financing to Close Concurrently with Close of Merger with Marker Therapeutics PR...
TapImmune to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire JACKSONVILLE, Fla., May 31, 2018 JACKSONVILLE, Fla., May 31, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ:...
TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum PR Newswire JACKSONVILLE, Fla., May 30, 2018 JACKSONVILLE, Fla., May 30, 2018 /PRNewswire/ -- TapImmune...
TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform PR Newswire JACKSONVILLE, Fla., May...
TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center PR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions